Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrei Shavnya is active.

Publication


Featured researches published by Andrei Shavnya.


Organic Letters | 2014

Synthesis of sulfones from organozinc reagents, DABSO, and alkyl halides.

Benjamin N. Rocke; Kevin B. Bahnck; Michael Herr; Sophie Y. Lavergne; Vincent Mascitti; Christian Perreault; Jana Polivkova; Andrei Shavnya

Organozinc reagents react with the SO2 surrogate DABSO, and the resulting zinc sulfinate salts are alkylated in situ to afford sulfones. This transformation has a broad scope and is compatible with a wide range of structural motifs of medicinal chemistry relevance including nitrile, secondary carbamates, and nitrogen-containing heterocycles.


Organic Letters | 2013

Palladium-Catalyzed Sulfination of Aryl and Heteroaryl Halides: Direct Access to Sulfones and Sulfonamides

Andrei Shavnya; Steven B. Coffey; Aaron Smith; Vincent Mascitti

A novel palladium-catalyzed sulfination of aryl and heteroaryl halides is described. This reaction operates under mild conditions and provides access to a wide range of aryl and heteroaryl sulfinates, a useful and versatile class of synthetic intermediates. Capitalizing on this sulfination reaction, one-pot protocols allowing direct access to sulfones and sulfonamides have also been developed. The practicality of these transformations is illustrated with the parallel synthesis of analogues of the drug Viagra.


ACS Medicinal Chemistry Letters | 2012

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.

Michael John Munchhof; Qifang Li; Andrei Shavnya; Gary Borzillo; Tracey L. Boyden; Christopher S. Jones; Susan Deborah Lagreca; Luis Martinez-Alsina; Nandini Chaturbhai Patel; Kathleen Pelletier; Larry A. Reiter; Michael D. Robbins; George T. Tkalcevic

Inhibitors of the Hedgehog signaling pathway have generated a great deal of interest in the oncology area due to the mounting evidence of their potential to provide promising therapeutic options for patients. Herein, we describe the discovery strategy to overcome the issues inherent in lead structure 1 that resulted in the identification of Smoothened inhibitor 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea (PF-04449913, 26), which has been advanced to human clinical studies.


Bioorganic & Medicinal Chemistry Letters | 2008

Comparative structure–activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition

Subas M. Sakya; Andrei Shavnya; Hengmiao Cheng; Chao Li; Bryson Rast; Jin Li; David A. Koss; Burton H. Jaynes; Donald W. Mann; Carol F. Petras; Scott B. Seibel; Michelle L. Haven; Michael P. Lynch

Structure-activity relationship (SAR) studies of novel 5-alkyl and 5-aryl/heteroaryl substituted 1,2,4-triazoles are described. The in vitro activity is compared to the pyrazole class of compounds with analogous side chains to delineate the contribution of the triazole ring nitrogen in binding to the active site. Both series are quite potent and selective in the canine whole blood (CWB) COX-2 assay, suggesting the increased binding contribution of the hydrophobic side chains.


Bioorganic & Medicinal Chemistry Letters | 2010

Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor.

Amy S. Antipas; Laura Cook Blumberg; Matthew Frank Brown; Jeffrey M. Casavant; Jonathan L. Doty; James P. Driscoll; Thomas M. Harris; Christopher S. Jones; Sandra P. McCurdy; Eric McElroy; Mark J. Mitton-Fry; Michael John Munchhof; David A. Reim; Lawrence A. Reiter; Sharon L. Ripp; Andrei Shavnya; Marc I. Smeets; Kristen A. Trevena

5-F substitution of an aminothiazole moiety within a series of thrombopoietin receptor agonists leads to potent agents with an improved hepatic safety profile in rodent toxicology studies.


Bioorganic & Medicinal Chemistry Letters | 2009

The identification of orally bioavailable thrombopoietin agonists.

Michael John Munchhof; Amy S. Antipas; Laura Cook Blumberg; Matthew Frank Brown; Jeffrey M. Casavant; Jonathan L. Doty; James P. Driscoll; Thomas M. Harris; Lilli A. Wolf-Gouveia; Christopher S. Jones; Qifang Li; Robert Gerald Linde; Paul D. Lira; Anthony Marfat; Eric McElroy; Mark J. Mitton-Fry; Sandra P. McCurdy; Lawrence A. Reiter; Sharon L. Ripp; Andrei Shavnya; Lisa Marie Thomasco; Kristen A. Trevena

Recently, we disclosed a series of potent pyrimidine benzamide-based thrombopoietin receptor agonists. Unfortunately, the structural features required for the desired activity conferred physicochemical properties that were not favorable for the development of an oral agent. The physical properties of the series were improved by replacing the aminopyrimidinyl group with a piperidine-4-carboxylic acid moiety. The resulting compounds possessed favorable in vivo pharmacokinetic properties, including good bioavailability.


Bioorganic & Medicinal Chemistry Letters | 2006

5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog

Subas M. Sakya; Kristin Lundy DeMello; Martha L. Minich; Bryson Rast; Andrei Shavnya; Robert J. Rafka; David A. Koss; Hengmiao Cheng; Jin Li; Burton H. Jaynes; Carl Bernard Ziegler; Donald W. Mann; Carol F. Petras; Scott B. Seibel; Annette M. Silvia; David M. George; Lisa A. Lund; Suzanne H. St. Denis; Anne Hickman; Michelle L. Haven; Michael P. Lynch


Bioorganic & Medicinal Chemistry Letters | 2004

Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine.

Jin Li; Kristin Lundy DeMello; Henry Cheng; Subas M. Sakya; Brian Scott Bronk; Robert J. Rafka; Burton H. Jaynes; Carl Bernard Ziegler; Carolyn Rose Kilroy; Donald W. Mann; Eric L. Nimz; Michael P. Lynch; Michelle L. Haven; Nicole L. Kolosko; Martha L. Minich; Chao Li; Jason K. Dutra; Bryson Rast; Rhonda Marie Crosson; Barry James Morton; Glen W. Kirk; Kathleen M. Callaghan; David A. Koss; Andrei Shavnya; Lisa A. Lund; Scott B. Seibel; Carol F. Petras; Annette M. Silvia


Bioorganic & Medicinal Chemistry Letters | 2007

Pyrimidine benzamide-based thrombopoietin receptor agonists.

Lawrence A. Reiter; Chakrapani Subramanyam; Emilio J. Mangual; Christopher S. Jones; Marc I. Smeets; Sandra P. McCurdy; Paul D. Lira; Robert Gerald Linde; Qifang Li; Fangning Zhang; Amy S. Antipas; Laura Cook Blumberg; Jonathan L. Doty; James P. Driscoll; Michael John Munchhof; Sharon L. Ripp; Andrei Shavnya; Richard M. Shepard; Diana Sperger; Lisa Marie Thomasco; Kristen A. Trevena; Lilli A. Wolf-Gouveia; Liling Zhang


Bioorganic & Medicinal Chemistry Letters | 2007

5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: Molecular modeling studies on binding contribution of 1 -(5 -methylsulfonyl )pyrid -2 -yl and 4-nitrile

Subas M. Sakya; Xinjun Hou; Martha L. Minich; Bryson Rast; Andrei Shavnya; Kristin Lundy DeMello; Hengmiao Cheng; Jin Li; Burton H. Jaynes; Donald W. Mann; Carol F. Petras; Scott B. Seibel; Michelle L. Haven

Researchain Logo
Decentralizing Knowledge